This study exists to compare options and see whether a medication treatment offers something meaningfully different. Researchers are trying to understand what a medication treatment could change in day-to-day care and decision-making.

In United States

ADHDDrugFrom 6 Years to 17 Years

Countries: United States
Sponsor: Arbor Pharmaceuticals, Inc.
Condition: ADHD

View study

CompletedNCT04075890

Arbitration Between Habitual and Goal-directed Behavior in OCD: Circuit Dynamics and Effects of Noninvasive Neurostimulation

This summary needs review. Please check the official study record and contact the research team for details.

In United States

OCDDeviceFrom 18 Years to 65 Years

Countries: United States
Sponsor: University of California, Los Angeles
Condition: OCD

View study

CompletedNCT00489866

Aripiprazole Augmentation of Antidepressants in PTSD

This summary needs review. Please check the official study record and contact the research team for details.

In United States

PTSDDrugFrom 18 Years to 65 Years

Countries: United States
Sponsor: Durham VA Medical Center
Condition: PTSD

View study

CompletedNCT02918370

Aripiprazole for Bipolarity and Addiction

This study exists to understand how a medication treatment holds up over time after the earliest research stage. Researchers are trying to understand whether a medication treatment can work better when mental health difficulties overlap with substance use.

In United States

Bipolarity, AddictionDrugFrom 18 Years to 65 Years

Countries: United States
Sponsor: University of Texas Southwestern Medical Center
Condition: Bipolarity, Addiction

View study

CompletedNCT00181779

Aripiprazole for Mania in Children and Adolescents With Bipolarity

This summary needs review. Please check the official study record and contact the research team for details.

In United States

BipolarityDrugFrom 6 Years to 17 Years

Countries: United States
Sponsor: Massachusetts General Hospital
Condition: Bipolarity

View study

CompletedNCT00102063

Aripiprazole in Adolescents With Schizophrenia

This summary needs review. Please check the official study record and contact the research team for details.

In United States

SchizophreniaDrugFrom 13 Years to 17 Years

Countries: United States
Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition: Schizophrenia

View study

Data coverage

Public registry coverage is progressing

HopeStage gathers information about mental health clinical trials from the public registries we currently index. We are progressively improving registry coverage, but this does not mean that every study in the world is already included.